(VIANEWS) – BanColombia S.A. (CIB), Harmony Biosciences Holdings (HRMY), CNB Financial Corporation (CCNE) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. BanColombia S.A. (CIB)

119% sales growth and 18.64% return on equity

Bancolombia S. A. offers a variety of banking services and products to individuals and corporations in Colombia, Panama and Puerto Rico. Nine segments make up the company: Banking Colombia; Banking Panama; Banking El Salvador; Banking Guatemala; Trust, Investment Banking and Brokerage. Fixed term deposits and checking accounts are offered. There is also trade financing available through domestic banks. Working capital loans can be obtained, as well as credit cards and personal loans. Overdrafts, mortgages, financial services and financial support for real estate developers. It also offers hedging options such as futures and forwards, options and swaps. The brokerage, investment advisory and private banking services include selling and distributing equities and futures in foreign currencies, fixed-income securities, mutual funds and structured products. It also offers foreign currency transaction services, cash management, life, auto and commercial insurance, as well as online and computer banking. The company also offers investment banking services that include project and acquisition financing, debt and equity capital market, principal investments and M&A restructurings and structured financing. It also provides money market accounts, mutual funds, pension funds, private equity fund, corporate trust and payment trust. It had 1,057 branches, 18,631 bank correspondents, 535 PAMs and 215 kiosks (El Salvador and Colombia) as well as 6,124 automated teller machines. Bancolombia S.A. is an institution that was founded in 1945. Its headquarters are in MedellAn in Colombia.

BanColombia S.A.’s sales growth this year is expected to be 85.3% and 12.4% for next year.

Year-on-year quarterly revenue growth grew by 44.6%, now sitting on N/A for the twelve trailing months.

Volume

Today’s last reported volume for BanColombia S.A. is 163518 which is 60.69% below its average volume of 415996.

BanColombia S.A.’s sales growth for the next quarter is 119%. The company’s growth estimates for the current quarter and the next is 126.7% and 296.7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.64%.

Volatility

BanColombia S.A.’s last day, last week, and last month’s current intraday variation average was 2.43%, 1.67%, and 1.61%, respectively.

BanColombia S.A.’s highest amplitude of average volatility was 2.29% (day), 2.34% (last week), and 2.50% (last month), respectively.

BanColombia S.A.’s Stock Yearly Top and Bottom Value

BanColombia S.A.’s stock is valued at $28.71 at 20:22 EST, way below its 52-week high of $45.98 and above its 52-week low of $26.27.

BanColombia S.A.’s Moving Average

BanColombia S.A.’s worth is below its 50-day moving average of $29.46 and way below its 200-day moving average of $34.95.

2. Harmony Biosciences Holdings (HRMY)

36.2% sales growth and 31.15% return on equity

Harmony Biosciences Holdings, Inc. is a pharmaceutical company at the commercial stage that develops and markets therapies for rare neurological conditions. WAKIX, the company’s drug product is used to treat excessive sleepiness among adults with narcolepsy. In February 2020, Harmony Biosciences II, Inc. was the company’s name. The company changed its name from Harmony Biosciences II, Inc. to Harmony Biosciences Holdings, Inc. Harmony Biosciences Holdings, Inc. is an organization that was founded in 2017. Its headquarters are in Plymouth Meeting, Pennsylvania.

Harmony Biosciences Holdings’s sales growth this year is expected to be 40.8% and 37.2% for next year.

Year-on-year quarterly revenue growth grew by 45%, now sitting on 364.29M for the twelve trailing months.

Volume

Today’s last reported volume for Harmony Biosciences Holdings is 388385 which is 31.94% below its average volume of 570663.

Harmony Biosciences Holdings’s sales growth for the next quarter is 36.2%. The company’s growth estimates for the ongoing quarter and the next is 217.6% and 36.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.15%.

Volatility

Harmony Biosciences Holdings’s last day, last week, and last month’s current intraday variation average was 0.94%, 0.72%, and 1.83%, respectively.

Harmony Biosciences Holdings’s highest amplitude of average volatility was 2.60% (day), 2.96% (last week), and 3.77% (last month), respectively.

Harmony Biosciences Holdings’s Stock Yearly Top and Bottom Value

Harmony Biosciences Holdings’s stock is valued at $42.47 at 20:22 EST, way under its 52-week high of $57.13 and way above its 52-week low of $31.54.

Harmony Biosciences Holdings’s Moving Average

Harmony Biosciences Holdings’s value is way below its 50-day moving average of $48.39 and below its 200-day moving average of $44.62.

3. CNB Financial Corporation (CCNE)

22.4% sales growth and 14.11% return on equity

CNB Financial Corporation is the bank holding firm for CNB Bank. It offers a variety of banking services and products for individuals, businesses, governmental and institutional customers. It accepts time, saving, and checking accounts. The bank also offers residential, real estate, industrial and residential loans as well as other specialized services. The company also offers trust and asset management services. These include the administration of trusts and estates as well as retirement plans and employee benefits plans. It also provides a variety of wealth management services. The company also invests in equity and debt securities, sells nonproprietary insurance products and annuities; small balance unsecured loans; secured loans that are primarily collateralized with automobiles or equipment. The company had a private banking division, one loan production and one drive-up offices, as well as 44 full-service locations in Pennsylvania, Ohio and New York. CNB Financial Corporation was established in Clearfield (PA) in 1865.

CNB Financial Corporation’s sales growth this year is expected to be 19.6% and 13.1% for next year.

Year-on-year quarterly revenue growth grew by 16.6%, now sitting on 199.95M for the twelve trailing months.

Volume

Today’s last reported volume for CNB Financial Corporation is 100704 which is 300.19% above its average volume of 25164.

CNB Financial Corporation’s sales growth is a negative 0% for the present quarter and 22.4% for the next. The company’s growth estimates for the current quarter and the next is 18.3% and 25.3%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.11%.

Volatility

CNB Financial Corporation’s last day, last week, and last month’s current intraday variation average was 4.49%, 1.93%, and 1.41%, respectively.

CNB Financial Corporation’s highest amplitude of average volatility was 7.60% (day), 2.96% (last week), and 2.48% (last month), respectively.

CNB Financial Corporation’s Stock Yearly Top and Bottom Value

CNB Financial Corporation’s stock is valued at $23.99 at 20:22 EST, way below its 52-week high of $28.59 and higher than its 52-week low of $23.00.

CNB Financial Corporation’s Moving Average

CNB Financial Corporation’s worth is below its 50-day moving average of $25.89 and below its 200-day moving average of $25.97.

4. Corcept Therapeutics Incorporated (CORT)

13.4% sales growth and 23.36% return on equity

Corcept Therapeutics Incorporated develops and markets drugs to treat severe metabolic and oncologic disorders. Korlym (mifepristone), a once daily oral medication, is offered to treat hyperglycemia secondary hypercortisolism among adult Cushing’s patients. This treatment can be used for type 2 diabetes or other conditions that result in the need for insulin. The company is currently developing relacorilant for Cushing’s patients; and nabpaclitaxel combined with relacorilant. Phase II clinical trials have been completed to treat serous ovarian cancers. Phase III clinical trials are underway to treat solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated is located in Menlo Park in California. It was established in 1998.

Corcept Therapeutics Incorporated’s sales growth this year is anticipated to be 13.9% and 11.2% for next year.

Year-on-year quarterly revenue growth grew by 12.9%, now sitting on 392.03M for the twelve trailing months.

Volume

Today’s last reported volume for Corcept Therapeutics Incorporated is 857306 which is 33.37% above its average volume of 642780.

Corcept Therapeutics Incorporated’s sales growth is a negative 0% for the current quarter and 13.4% for the next. The company’s growth estimates for the present quarter and the next is a negative 8.3% and negative -11.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.36%.

Volatility

Corcept Therapeutics Incorporated’s last day, last week, and last month’s current intraday variation average was 1.23%, 0.70%, and 1.21%, respectively.

Corcept Therapeutics Incorporated’s highest amplitude of average volatility was 2.69% (day), 2.04% (last week), and 2.77% (last month), respectively.

Corcept Therapeutics Incorporated’s Stock Yearly Top and Bottom Value

Corcept Therapeutics Incorporated’s stock is valued at $25.49 at 20:22 EST, way under its 52-week high of $29.93 and way higher than its 52-week low of $15.83.

Corcept Therapeutics Incorporated’s Moving Average

Corcept Therapeutics Incorporated’s worth is below its 50-day moving average of $27.12 and way higher than its 200-day moving average of $22.79.

5. Cooper Companies (COO)

11.4% sales growth and 14.39% return on equity

Together with its subsidiaries, The Cooper Companies, Inc. develops, produces, and markets contact lenses. CooperVision is one segment, while CooperSurgical is the other. CooperVision offers both spherical lenses, which correct near- and farsightedness, as well as multifocal and toric lenses. These lenses can correct vision problems such as presbyopia and myopia in Americas, Europe and the Middle East as well as eye fatigues and ocular dryness. CooperSurgical is a segment that focuses on women and their health. It provides contraception, medical devices and genomics to healthcare professionals worldwide. The company offers office and surgical products including PARAGARD and uterine manipulators as well as retractors and closures, point-of-care products, LEEP products and endosee products. It also provides fertility products and services such fertilization consumables, equipment and embryo options. It was established in 1958 by The Cooper Companies, Inc. and has its headquarters in San Ramon, California.

Cooper Companies’s sales growth this year is expected to be 12.8% and 6.5% for next year.

Year-on-year quarterly revenue growth grew by 15.3%, now sitting on 3.14B for the twelve trailing months.

Volume

Today’s last reported volume for Cooper Companies is 344834 which is 16.11% above its average volume of 296974.

Cooper Companies’s sales growth is a negative 0% for the present quarter and 11.4% for the next. The company’s growth estimates for the present quarter and the next is a negative 5% and 4.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.39%.

Volatility

Cooper Companies’s last day, last week, and last month’s current intraday variation average was 0.54%, 1.34%, and 1.90%, respectively.

Cooper Companies’s highest amplitude of average volatility was 2.38% (day), 2.50% (last week), and 2.78% (last month), respectively.

Cooper Companies’s Stock Yearly Top and Bottom Value

Cooper Companies’s stock is valued at $0.00 at 20:22 EST, under its 52-week low of $270.04.

Cooper Companies’s Moving Average

Cooper Companies’s worth is below its 50-day moving average of $310.35 and below its 200-day moving average of $360.45.

6. Reynolds Consumer Products (REYN)

11.2% sales growth and 15.87% return on equity

Reynolds Consumer Products Inc. manufactures and markets products for the cooking, waste, storage and tableware categories. There are four main segments to it: Reynolds Cooking & Baking; Hefty Waste & Storage; Hefty Tableware; and Presto Products. Reynolds Cooking & Baking produces foil, aluminum pans, paper for baking, paper for freezer, paper for cooking, paper for wrapping food in, paper bags and paper wrap for slow cookers. It is also available under Reynolds Wrap, Reynolds KITCHENS and E-Z Foil brand names in the United States. Hefty Waste & Storage offers garbage bags and food storage bags, both under the Hefty Ultra Strong or Hefty Strong brand. The Hefty EnergyBag program, which includes blue, clear, plastic, recyclable, and compostable bags as well as bags made of recycled materials and bags made from them, is also available in this segment. Hefty Tableware offers disposable and compostable dishes, plates, platters and cups under its Hefty brand. Presto Products sells only store-brand products, including food storage bags and trash bags as well as reusable storage containers. Reynolds Consumer Products Inc. sells both store and brand-name products to supermarkets, bulk merchants, warehouse clubs and discount chains. They also offer dollar stores and drug stores as well as home improvement and military stores. It was established in 1947 in Lake Forest, Illinois. Reynolds Consumer Products Inc. is a subsidiary to Packaging Finance Limited.

Reynolds Consumer Products’s sales growth this year is anticipated to be 9.2% and 3.1% for next year.

Year-on-year quarterly revenue growth grew by 5%, now sitting on 3.69B for the twelve trailing months.

Volume

Today’s last reported volume for Reynolds Consumer Products is 119059 which is 69.27% below its average volume of 387461.

Reynolds Consumer Products’s sales growth for the next quarter is 11.2%. The company’s growth estimates for the ongoing quarter and the next is a negative 30.3% and 21.6%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.87%.

Volatility

Reynolds Consumer Products’s last day, last week, and last month’s current intraday variation average was 1.81%, 0.76%, and 0.65%, respectively.

Reynolds Consumer Products’s highest amplitude of average volatility was 1.44% (day), 2.17% (last week), and 1.97% (last month), respectively.

Reynolds Consumer Products’s Stock Yearly Top and Bottom Value

Reynolds Consumer Products’s stock is valued at $27.70 at 20:22 EST, way below its 52-week high of $32.29 and way above its 52-week low of $24.54.

Reynolds Consumer Products’s Moving Average

Reynolds Consumer Products’s value is below its 50-day moving average of $28.40 and below its 200-day moving average of $29.04.

7. TrustCo Bank Corp NY (TRST)

10.3% sales growth and 11.59% return on equity

TrustCo Bank Corp NY is the holding company of Trustco Bank. Trustco Bank is a federal savings bank providing personal and business banking to individuals, corporations, partnerships and companies. It accepts deposits and provides loans and investment options. The company also acts as an investment trust for real estate. It acquires and holds real estate assets including mortgage-backed securities and residential mortgage loans. The company also serves as an executor and trustee of personal estates, provides asset and wealth management and estate planning, as well as custodial and other services. It is also a trustee for various employee benefits plans and corporate pensions and profit sharing trusts. It had 148 banks and 164 automated teller machines across New York, New Jersey and Vermont as of December 31, 2020. Glenville is the headquarters of this company, which was established in 1902.

TrustCo Bank Corp NY’s sales growth this year is anticipated to be 7% and 4.7% for next year.

Year-on-year quarterly revenue growth grew by 8.2%, now sitting on 188.75M for the twelve trailing months.

Volume

Today’s last reported volume for TrustCo Bank Corp NY is 47028 which is 34.02% below its average volume of 71284.

TrustCo Bank Corp NY’s sales growth for the next quarter is 10.3%. The company’s growth estimates for the ongoing quarter and the next is a negative 3.4% and 1.2%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.59%.

Volatility

TrustCo Bank Corp NY’s last day, last week, and last month’s current intraday variation average was 0.06%, 0.70%, and 0.98%, respectively.

TrustCo Bank Corp NY’s highest amplitude of average volatility was 1.18% (day), 2.62% (last week), and 2.08% (last month), respectively.

TrustCo Bank Corp NY’s Stock Yearly Top and Bottom Value

TrustCo Bank Corp NY’s stock is valued at $34.15 at 20:22 EST, under its 52-week high of $37.10 and way higher than its 52-week low of $29.50.

TrustCo Bank Corp NY’s Moving Average

TrustCo Bank Corp NY’s value is above its 50-day moving average of $33.50 and higher than its 200-day moving average of $32.75.

8. SS&C Technologies Holdings (SSNC)

6.9% sales growth and 12.02% return on equity

SS&C Technologies Holdings, Inc., along with its subsidiaries, offers software products and services that are software-enabled to the financial and healthcare sectors. It owns and manages technology across the following areas: securities accounting, front-office operations, including trading and modeling, middle-office activities include portfolio management or reporting and back-office tasks such as accounting, performance, reconciliation, reporting and processing, tax reporting and compliance. Healthcare solutions comprise claims adjudication and benefit management as well as care management and business intelligence. The company’s services enable professionals working in healthcare and financial services to simplify complex business processes. They also help clients manage their information processing needs. Software-enabled services offered by the company include SS&C GlobeOp and Global Investor and Distribution Solutions. SS&C Retirement Solutions. Bluedoor. Advent Outsourcing Services. Advent Data Solutions. ALPS Advisors. Virtual Data Rooms. Also, pharmacy and healthcare administration. Software products include portfolio/investment and analytic software, portfolio management and trading software, digital processes automation product suites, banking and lending solutions as well as research and analysis, risk and training solutions. It also offers professional services such as consulting, implementation and support services for clients. The company operates across the United States, Canada, Japan, Europe, Middle East and Africa, as well as the United Kingdom, Europe, Middle East and Africa, Asia Pacific, Japan, Canada, and the Americas. It was established in 1986. The headquarters are located in Windsor, Connecticut.

SS&C Technologies Holdings’s sales growth this year is expected to be 6.2% and 4.8% for next year.

Year-on-year quarterly revenue growth grew by 5.5%, now sitting on 5.18B for the twelve trailing months.

Volume

Today’s last reported volume for SS&C Technologies Holdings is 1610250 which is 12.81% above its average volume of 1427360.

SS&C Technologies Holdings’s sales growth for the next quarter is 6.9%. The company’s growth estimates for the ongoing quarter and the next is a negative 10.6% and negative 0%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.02%.

Volatility

SS&C Technologies Holdings’s last day, last week, and last month’s current intraday variation average was 3.19%, 1.41%, and 1.38%, respectively.

SS&C Technologies Holdings’s highest amplitude of average volatility was 3.83% (day), 2.27% (last week), and 2.22% (last month), respectively.

SS&C Technologies Holdings’s Stock Yearly Top and Bottom Value

SS&C Technologies Holdings’s stock is valued at $49.47 at 20:22 EST, way under its 52-week high of $84.85 and above its 52-week low of $48.85.

SS&C Technologies Holdings’s Moving Average

SS&C Technologies Holdings’s value is way under its 50-day moving average of $58.29 and way under its 200-day moving average of $68.21.

LEAVE A REPLY

Please enter your comment!
Please enter your name here